Pyxis Oncology Inc (NASDAQ: PYXS) on Monday, soared 6.59% from the previous trading day, before settling in for the closing price of $1.67. Within the past 52 weeks, PYXS’s price has moved between $1.64 and $6.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 41.24%. With a float of $41.12 million, this company’s outstanding shares have now reached $59.45 million.
Let’s determine the extent of company efficiency that accounts for 50 employees. In terms of profitability, gross margin is 84.98%, operating margin of -343.24%, and the pretax margin is -293.15%.
Pyxis Oncology Inc (PYXS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Pyxis Oncology Inc is 30.85%, while institutional ownership is 51.89%. The most recent insider transaction that took place on Nov 26 ’24, was worth 174,364. In this transaction CFO & COO of this company bought 88,850 shares at a rate of $1.96, taking the stock ownership to the 1,199,143 shares.
Pyxis Oncology Inc (PYXS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 41.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 34.60% during the next five years compared to -118.72% drop over the previous five years of trading.
Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators
Pyxis Oncology Inc (PYXS) is currently performing well based on its current performance indicators. A quick ratio of 7.33 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.05, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.21 in one year’s time.
Technical Analysis of Pyxis Oncology Inc (PYXS)
Looking closely at Pyxis Oncology Inc (NASDAQ: PYXS), its last 5-days average volume was 1.49 million, which is a jump from its year-to-date volume of 0.78 million. As of the previous 9 days, the stock’s Stochastic %D was 12.59%. Additionally, its Average True Range was 0.27.
During the past 100 days, Pyxis Oncology Inc’s (PYXS) raw stochastic average was set at 3.48%, which indicates a significant decrease from 4.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 249.51% in the past 14 days, which was higher than the 118.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.2831, while its 200-day Moving Average is $3.8896. However, in the short run, Pyxis Oncology Inc’s stock first resistance to watch stands at $1.8267. Second resistance stands at $1.8733. The third major resistance level sits at $1.9267. If the price goes on to break the first support level at $1.7267, it is likely to go to the next support level at $1.6733. Now, if the price goes above the second support level, the third support stands at $1.6267.
Pyxis Oncology Inc (NASDAQ: PYXS) Key Stats
Market capitalization of the company is 103.98 million based on 59,466K outstanding shares. Right now, sales total 0 K and income totals -73,790 K. The company made 0 K in profit during its latest quarter, and -17,300 K in sales during its previous quarter.
